meglumine antimoniate has been researched along with Canine Diseases in 96 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (6.25) | 18.7374 |
| 1990's | 21 (21.88) | 18.2507 |
| 2000's | 28 (29.17) | 29.6817 |
| 2010's | 33 (34.38) | 24.3611 |
| 2020's | 8 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aguiar-Soares, RDO; Andrade, HM; Brito, RCF; Cardoso, JMO; Frézard, F; Mathias, FAS; Ostolin, TLVDP; Ramos, GS; Reis, AB; Reis, LES; Roatt, BM; Vieira, JFP | 1 |
| Campos, MP; Figueiredo, FB; Gonçalves, AS; Gonçalves, G; Medeiros, LCS | 1 |
| Broere, F; de Jong, MK; Piek, CJ; Rappoldt, A | 1 |
| Daza González, MA; Fermín Rodríguez, M; Fragío Arnold, C; Miró, G; Rupérez Noguer, C | 1 |
| Apostolidis, K; Buono, A; Chatzis, MK; Kasabalis, D; Leontides, LS; Petanides, T; Polizopoulou, ZS; Saridomichelakis, MN; Steiner, JM; Suchodolski, JS; Xenoulis, PG | 1 |
| Arbeláez, N; Montoya, A; Moreno, J; Murillo, J; Robledo, SM; Vélez, A; Vélez, ID | 1 |
| Apostolidis, K; Athanasiou, LV; Chatzis, MK; Ikonomopoulos, J; Kasabalis, D; Leontides, LS; Mataragka, A; Petanides, T; Saridomichelakis, MN; Xenoulis, PG | 1 |
| Bitam, I; Davoust, B; Hamidat, HK; Lafri, I; Laidoudi, Y; Lounas, A; Mediannikov, O; Medkour, H; Mekroud, A; Varloud, M | 1 |
| Barbè, F; Ibba, F; Paltrinieri, S; Rossi, G | 1 |
| Chatzis, MK; Kasabalis, D; Saridomichelakis, MN; Steiner, JM; Suchodolski, JS; Xenoulis, PG | 1 |
| Burchmore, R; Ceron, JJ; Escribano, D; Horvatic, A; Kocaturk, M; Martinez-Subiela, S; Mrljak, V; Pardo-Marin, L; Yilmaz, Z | 1 |
| Alexandre-Pires, G; Alves-Azevedo, R; de Jesus, J; Ligeiro, D; Lopes-Ventura, S; Pereira da Fonseca, I; Pereira, MA; Rafael-Fernandes, M; Rodrigues, A; Santos, M; Santos-Gomes, G; Santos-Mateus, D; Tomás, AM; Valério-Bolas, A | 1 |
| Baneth, G; Marí-Martorell, D; Martínez-Orellana, P; Montserrat-Sangrà, S; Ordeix, L; Solano-Gallego, L | 1 |
| Cordeiro-da-Silva, A; Dantas-Torres, F; Miró, G; Travi, BL | 1 |
| Azevedo, EG; Caliari, MMV; Castro, RS; de Amorim, IFG; Demicheli, C; Frezard, FJG; Michalick, MSM; Mosser, DM; Pereira, RA; Pinheiro, LJ; Pinto, AJW; Silva, SM; Tafuri, WL | 1 |
| Acedo-Sánchez, C; Corpas-López, V; Díaz-Sáez, V; Martín-Sánchez, J; Merino-Espinosa, G; Morillas-Márquez, F; Navarro-Moll, MC | 1 |
| Cantos-Barreda, A; Cerón, JJ; Escribano, D; Martínez-Subiela, S; Pardo-Marín, L; Segarra, S | 1 |
| Bernal, LJ; Cantos-Barreda, A; Cerón, JJ; Escribano, D; Martínez-Subiela, S; Tecles, F | 1 |
| Cerón, JJ; Checa, R; Daza González, MA; Fermín Rodríguez, M; Fragío Arnold, C; Martínez Subiela, S; Miró, G; Montoya, A; Portero Fuentes, M; Rupérez Noguer, C | 1 |
| Gómez, S; Palacio, MJF; Santarelli, G; Sebastián-Marcos, P | 1 |
| Chatzis, MK; Kasabalis, D; Petanides, T; Saridomichelakis, MN; Steiner, JM; Suchodolski, JS; Xenoulis, PG | 2 |
| Campino, L; Henriques, S; Maia, C; Marques, M; Nunes, M; Rolão, N | 1 |
| Giordano, A; Ibba, F; Meazzi, S; Paltrinieri, S; Rossi, G | 1 |
| Chicharro, C; Lombardo, G; Lupo, T; Pennisi, MG; Solano-Gallego, L | 1 |
| Azevedo, EG; da Silva, SM; de Oliveira E Castro, RA; de Souza, LE; Demicheli, C; Ferreira, AA; Ferreira, CS; Frézard, F; Rezende, SA; Ribeiro, RR | 1 |
| Aoun, K; Harrat, Z; Laamrani El Idrissi, A; Marty, P | 1 |
| Cerrone, A; Corso, R; Galiero, G; Gravino, AE; Manna, L; Muzj, P | 1 |
| Altet, L; Di Filippo, L; Martínez-Orellana, P; Montserrat, S; Ordeix, L; Planellas, M; Roura, X; Solano-Gallego, L | 1 |
| Acedo-Sánchez, C; Corpas-López, V; Díaz-Sáez, V; Martín-Sánchez, J; Merino-Espinosa, G; Morillas-Márquez, F | 1 |
| Castanys, S; Corpas-López, V; Gamarro, F; García-Hernandez, R; Gómez Pérez, V; Martín-Sanchez, J; Tomás, AM | 1 |
| Alborch, L; Montserrat-Sangrà, S; Ordeix, L; Solano-Gallego, L | 1 |
| Cerón, JJ; Garcia-Martinez, JD; Martínez-Subiela, S; Pardo-Marín, L; Pastor, J; Segarra, S; Tvarijonaviciute, A | 1 |
| De Majo, M; Lo Giudice, S; Masucci, M; Pennisi, MG; Reale, S; Vitale, F | 1 |
| Foglia Manzillo, V; Gradoni, L; Guglielmino, R; Oliva, G; Pagano, A; Restucci, B | 1 |
| Bianciardi, P; Mateo, M; Maynard, L; Miró, G; Vischer, C | 1 |
| Arnedo-Pena, A; Bellido-Blasco, JB; Herrero-Carot, C; Romeo-García, MA | 1 |
| Avallone, L; Cestaro, A; Ciaramella, P; Cortese, L; Di Loria, A; Lombardi, P; Pelagalli, A; Piantedosi, D | 1 |
| Bertazzolo, W; Dell'Orco, M; Paccioretti, F | 1 |
| Lamothe, J | 2 |
| Bianciardi, P; Cañavate, C; Cruz, I; Miró, G; Mortarino, M; Oliva, G; Vischer, C | 1 |
| Bardagí, M; Ferrer, L; Ravera, I; Roura, X; Torres, M; Zanna, G | 1 |
| Descalzo, MA; Fraile, C; Gálvez, R; Miró, G; Molina, R | 1 |
| Giudice, E; Passantino, A | 1 |
| Amato, ME; De Palo, P; Greco, B; Lubas, G; Paradies, P; Sasanelli, M | 1 |
| Aït-Oudhia, K; Dedet, JP; Gazanion, E; Lachaud, L; Oury, B; Pratlong, F; Sereno, D | 1 |
| Albuquerque, C; Campino, L; Cardoso, L; Dias, I; Machado, J; Pires, MA; Requicha, J; Sargo, T; Viegas, C | 1 |
| Civitella, C; Guglielmini, C; Luciani, A; Sconza, S | 1 |
| Costa Val, AP; Demicheli, C; Frézard, F; Melo, MN; Michalick, MS; Rocha, OG; Schettini, DA; Souza, LF | 2 |
| Bernal, LJ; Cerón, JJ; Martínez-Subiela, S | 1 |
| Diaz-Bertrana, MC; Durall, I; Franch, J; Lafuente, P; Munilla, A; Pastor, J; Torrent, E | 1 |
| Aceña, MC; Castillo, JA; Gascón, M; Gómez-Ochoa, P; Miana-Mena, FJ | 1 |
| Dugas, B; Mazier, D; Pino, P; Rougier, S; Vouldoukis, I; Woehrlé, F | 1 |
| Aste, G; Boari, A; Di Tommaso, M; Steiner, JM; Williams, DA | 1 |
| Bonello, FL; de Lima, VM; Feitosa, MM; Ikeda-Garcia, FA; Lopes, RS; Marques, FJ; Morinishi, CK; Perri, SH; Zanette, MF | 1 |
| Cortes, S; João, A; Pereira, MA; Santos-Gomes, GM | 1 |
| Costa, M; Ferrer, L; Martorell, S; Miranda, S; Ramis, A | 1 |
| Ciarlini, PC; Feitosa, MM; Ikeda-Garcia, FA; Lima, VM; Lopes, RS; Marques, FJ; Perri, SH | 1 |
| Cadena, H; Tabares, CJ; Travi, BL | 1 |
| Gravino, AE; Manna, L; Pavone, LM; Picillo, E; Reale, S; Vitale, F | 1 |
| Avallone, L; Ciaramella, P; Cortese, L; Di Loria, A; Lombardi, P; Mastellone, V; Pelagalli, A; Piantedosi, D | 1 |
| Campos Neto, A; da Costa, RT; Dias, ES; França, JC; Fujiwara, RT; Mayrink, W; Miret, J; Nascimento, E; Reed, S; Sampaio, W; Vale, A; Vieira, E | 1 |
| Compagnoni, F; Franceschi, A; Mancianti, F | 1 |
| Alves, CF; Demicheli, C; Frézard, F; Melo, FA; Melo, MN; Michalick, MS; Moura, EP; Pimentel, VM; Ribeiro, RR; Sampaio, WM; Schettini, DA; Silva, SM; Tafuri, WL | 1 |
| Alving, CR; Chapman, WL; Hanson, WL; Hendricks, LD | 1 |
| Belloli, C; Carli, S; Ceci, L; De Natale, G; Marcotrigiano, G; Montesissa, C; Ormas, P; Tassi, P | 1 |
| da Costa, JM; Monjour, L; Neogy, AB; Vouldoukis, I | 1 |
| Alvar, J; Boggio, J; González, F; Molina, R; Nieto, J; Rodriguez, F; San Andrés, M; San Andrés, MD; Tesouro, M; Vitutia, M | 1 |
| Closa, JM; Font, A; Gines, C; Mascort, J | 1 |
| Arnold, P; Deplazes, P; Eckert, J; Lutz, H; Smith, NC | 1 |
| Alberola, J; Arboix, M; Esteban, M; Valladares, JE | 1 |
| Abate, O; Buracco, P; Guglielmino, R; Morello, E | 1 |
| Slappendel, RJ; Teske, E | 1 |
| Alberola, J; Arboix, M; Cristofol, C; Franquelo, C; Freixas, J; Valladares, JE | 1 |
| Boehringer, C; Bonnefont, C; Bourdoiseau, G; Chabanne, L; Hoareau, E; Stolle, T | 1 |
| Alberola, J; Arboix, M; Cristòfol, C; Franquelo, C; Gállego, M; Portús, M; Riera, C; Valladares, JE | 1 |
| Ciaramella, P; Cortese, L; de Luna, R; Gradoni, L; Oliva, G; Orsini, S; Persechino, A; Scalone, A | 1 |
| Amusategui, I; Sainz, A; Tesouro, MA | 2 |
| Alunda, JM; Cuquerella, M; de la Fuente, C; Fernández-Pérez, FJ; Gómez, MT; Méndez, S | 1 |
| Belloli, C; Bertini, S; Carli, S; Crescenzo, G; Mengozzi, G; Ormas, P; Zaghini, A | 1 |
| Aisa, MJ; Alberola, J; Arboix, M; Carrió, J; Castillejo, S; Fisa, R; Gállego, M; Ribas, N; Riera, C; Valladares, JE | 1 |
| Greiner, M; Moritz, A; Steuber, S | 1 |
| Greiner, M; Moritz, A; Schirrmann, I; Steuber, S | 1 |
| Alberola, J; Arboix, M; Castillejo, S; Ferrer, L; Fisa, R; Gallego, M; Iniesta, L; Portús, M; Riera, C; Roura, X; Solano-Gallego, L; Valladares, JE | 1 |
| Carrió, J; Portús, M | 1 |
| Castillo, JA; Gracia, MJ; Guarga, JL; Lucientes, J; Moreno, J; Peribáñez, MA | 1 |
| Gradoni, L; Gramiccia, M; Orsini, S | 1 |
| Arnold, P; Deplazes, P; Gessler, M; Skaggs, J | 1 |
| Gradoni, L; Gramiccia, M; Mancianti, F; Maroli, M | 1 |
| Gradoni, L; Gramiccia, M; Mancianti, F; Pieri, S | 2 |
| Benderitter, T; Casanova, P; Nashkidachvili, L; Quilici, M | 1 |
| de Souza, PE; Pimentel, PS; Senra, MS | 1 |
1 review(s) available for meglumine antimoniate and Canine Diseases
| Article | Year |
|---|---|
Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Reservoirs; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Molecular Diagnostic Techniques; Organometallic Compounds; Phosphorylcholine; Point-of-Care Systems; Serologic Tests | 2018 |
14 trial(s) available for meglumine antimoniate and Canine Diseases
| Article | Year |
|---|---|
Evaluation of nephrotoxicity and ototoxicity of aminosidine (paromomycin)-allopurinol combination in dogs with leishmaniosis due to Leishmania infantum: A randomized, blinded, controlled study.
Topics: Allopurinol; Animals; Cochlea; Creatinine; Dog Diseases; Dogs; Double-Blind Method; Drug Combinations; Evoked Potentials, Auditory, Brain Stem; Female; Hearing; Hearing Loss; Injections, Subcutaneous; Kidney; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine Antimoniate; Neurologic Examination; Paromomycin; Random Allocation; Vestibule, Labyrinth | 2019 |
A randomized, blinded, controlled clinical trial comparing the efficacy of aminosidine (paromomycin)-allopurinol combination with the efficacy of meglumine antimoniate-allopurinol combination for the treatment of canine leishmaniosis due to Leishmania inf
Topics: Allopurinol; Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Injections, Subcutaneous; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine Antimoniate; Paromomycin; Trypanocidal Agents | 2020 |
Potential of Artesunate in the treatment of visceral leishmaniasis in dogs naturally infected by Leishmania infantum: Efficacy evidence from a randomized field trial.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Artesunate; Dog Diseases; Dogs; Female; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine Antimoniate; Parasite Load; Parasitemia; Zoonoses | 2020 |
Effectiveness of the sesquiterpene (-)-α-bisabolol in dogs with naturally acquired canine leishmaniosis: an exploratory clinical trial.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Monocyclic Sesquiterpenes; Organometallic Compounds; Parasite Load; Sesquiterpenes; Treatment Outcome | 2018 |
Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Retrospective Studies | 2015 |
Clinical efficacy of two different drug combinations for the treatment of canine leishmaniasis.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Leishmaniasis; Meglumine; Meglumine Antimoniate; Metronidazole; Organometallic Compounds; Spiramycin; Treatment Outcome | 2008 |
Effects of therapy on haemostasis in dogs infected with Leishmania infantum, Ehrlichia canis, or both combined.
Topics: Allopurinol; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Dog Diseases; Dogs; Doxycycline; Drug Combinations; Ehrlichia canis; Ehrlichiosis; Enzyme Inhibitors; Female; Hemostasis; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Platelet Aggregation; Treatment Outcome | 2009 |
Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.
Topics: Allopurinol; Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2009 |
Monitoring the reverse to normal of clinico-pathological findings and the disease free interval time using four different treatment protocols for canine leishmaniosis in an endemic area.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Endemic Diseases; Female; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Time Factors | 2012 |
Serum concentrations of acute-phase proteins in dogs with leishmaniosis during short-term treatment.
Topics: Acute-Phase Proteins; Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Administration Schedule; Drug Therapy, Combination; Female; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2003 |
Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Leishmaniasis, Cutaneous; Lymphocyte Subsets; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Time Factors | 2007 |
Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniosis. Veterinary Group of Lupino.
Topics: Animals; Antigens, Protozoan; Antiprotozoal Agents; Combined Modality Therapy; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Lymphocytes; Macrophages; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1994 |
The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial.
Topics: Animals; Antimony; Antiprotozoal Agents; Disease-Free Survival; Dog Diseases; Dogs; Female; Injections, Intravenous; Injections, Subcutaneous; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Recurrence; Remission Induction; Treatment Outcome | 1997 |
Clinical follow-up examination after treatment of canine leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Follow-Up Studies; Leishmania infantum; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 1998 |
81 other study(ies) available for meglumine antimoniate and Canine Diseases
| Article | Year |
|---|---|
Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.
Topics: Allopurinol; Animals; Antibodies, Monoclonal; CD4-Positive T-Lymphocytes; Dog Diseases; Dogs; Immunologic Factors; Immunotherapy; Leishmania infantum; Leishmaniasis, Visceral; Liposomes; Meglumine Antimoniate; Organometallic Compounds; Polyethylene Glycols; Receptors, Interleukin-10 | 2022 |
Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Resistance; Female; Leishmania infantum; Leishmaniasis, Visceral; Meglumine Antimoniate; Phosphorylcholine | 2021 |
Survival time and prognostic factors in canine leishmaniosis in a non-endemic country treated with a two-phase protocol including initial allopurinol monotherapy.
Topics: Allopurinol; Animals; Creatinine; Dog Diseases; Dogs; Humans; Leishmania infantum; Leishmaniasis; Leishmaniasis, Visceral; Meglumine Antimoniate; Prognosis; Recurrence; Urea | 2023 |
Short term impacts of meglumine antimoniate treatment on kidney function in dogs with clinical leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Biomarkers; Creatinine; Dog Diseases; Dogs; Female; Glomerular Filtration Rate; Kidney Diseases; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine Antimoniate | 2019 |
First Report of an Urban Case of Canine Visceral Leishmaniasis in the Municipality of Cali, Colombia.
Topics: Allopurinol; Animals; Antimetabolites; Antiprotozoal Agents; Base Sequence; Cities; Colombia; DNA, Protozoan; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine Antimoniate | 2020 |
Influence of domperidone supplementation on short-term changes in C-reactive protein and paraoxonase-1 in dogs with leishmaniasis undergoing meglumine antimoniate and allopurinol therapy.
Topics: Allopurinol; Animals; Aryldialkylphosphatase; C-Reactive Protein; Dietary Supplements; Dog Diseases; Dogs; Domperidone; Leishmaniasis; Meglumine Antimoniate | 2020 |
Serum cobalamin concentrations in dogs with leishmaniosis before and during treatment.
Topics: Allopurinol; Animals; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis; Leishmaniasis, Visceral; Meglumine Antimoniate; Vitamin B 12 | 2021 |
Identification of novel biomarkers for treatment monitoring in canine leishmaniosis by high-resolution quantitative proteomic analysis.
Topics: Acute-Phase Proteins; Allopurinol; Animals; Antiprotozoal Agents; Biomarkers; Dog Diseases; Dogs; Female; Ferritins; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Proteomics; Serum Globulins | 2017 |
Leishmania infantum exerts immunomodulation in canine Kupffer cells reverted by meglumine antimoniate.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Kupffer Cells; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2017 |
Leishmania infantum-specific IFN-γ production in stimulated blood from dogs with clinical leishmaniosis at diagnosis and during treatment.
Topics: Allopurinol; Animals; Dog Diseases; Dogs; Female; Interferon-gamma; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Trypanocidal Agents | 2017 |
Hepatic fibropoiesis in dogs naturally infected with Leishmania (Leishmania) infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Gene Expression Regulation; Leishmania infantum; Leishmaniasis, Visceral; Liposomes; Liver; Liver Cirrhosis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Random Allocation; Transforming Growth Factor beta; Vimentin | 2018 |
Changes in serum anti-Leishmania antibody concentrations measured by time-resolved immunofluorometric assays in dogs with leishmaniosis after treatment.
Topics: Allopurinol; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Enzyme-Linked Immunosorbent Assay; Fluoroimmunoassay; Immunoglobulin A; Immunoglobulin G; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2018 |
Changes in the concentration of anti-Leishmania antibodies in saliva of dogs with clinical leishmaniosis after short-term treatment.
Topics: Allopurinol; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Saliva | 2018 |
Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis.
Topics: Acute-Phase Proteins; Allopurinol; Animals; Antiprotozoal Agents; Aryldialkylphosphatase; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Meglumine Antimoniate; Phosphorylcholine | 2019 |
Canine leishmaniasis associated with pericardial effusion in a 4-year-old dog.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Cardiac Tamponade; Dog Diseases; Dogs; Echocardiography; Leishmania; Leishmaniasis; Meglumine Antimoniate; Pericardial Effusion; Pericardial Fluid | 2019 |
Thyroid function in 36 dogs with leishmaniosis due to Leishmania infantum before and during treatment with allopurinol with or without meglumine antimonate.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Hypothyroidism; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Thyrotropin; Thyroxine | 2013 |
In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Deoxycholic Acid; Disease Reservoirs; Dog Diseases; Dogs; Drug Combinations; Humans; Immunocompetence; Immunocompromised Host; Inhibitory Concentration 50; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Phosphorylcholine | 2013 |
Paraoxonase activity as a tool for clinical monitoring of dogs treated for canine leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Aryldialkylphosphatase; Biomarkers; Case-Control Studies; Dog Diseases; Dogs; Drug Therapy, Combination; Enzyme Activation; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2014 |
Papular dermatitis due to Leishmania infantum infection in seventeen dogs: diagnostic features, extent of the infection and treatment outcome.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Dermatitis; DNA, Protozoan; DNA, Ribosomal Spacer; Dog Diseases; Dogs; Female; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Molecular Typing; Organometallic Compounds; Prognosis; Protozoan Proteins; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Skin Tests; Treatment Outcome | 2014 |
Prospective evaluation of serum pancreatic lipase immunoreactivity and troponin I concentrations in Leishmania infantum-infected dogs treated with meglumine antimonate.
Topics: Animals; Antiparasitic Agents; Dog Diseases; Dogs; Female; Leishmania infantum; Leishmaniasis, Visceral; Lipase; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pancreas; Troponin I | 2014 |
Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Bone Marrow; Chemistry, Pharmaceutical; Dog Diseases; Dogs; Drug Carriers; Drug Delivery Systems; Female; Leishmania infantum; Leishmaniasis, Visceral; Liposomes; Liver; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasite Load; Polyethylene Glycols; Spleen | 2014 |
[Meeting "Visceral leishmaniasis in Maghreb", 2-4 April 2015 in Tunis. Recommendations].
Topics: Africa, Northern; Amphotericin B; Animals; Antiprotozoal Agents; Developing Countries; Disease Management; Disease Reservoirs; Dog Diseases; Dogs; Drug Substitution; Early Diagnosis; Humans; Immunologic Tests; Insect Control; Insect Vectors; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phlebotomus; Zoonoses | 2015 |
Early reduction of Leishmania infantum-specific antibodies and blood parasitemia during treatment in dogs with moderate or severe disease.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; DNA, Protozoan; Dog Diseases; Dogs; Enzyme-Linked Immunosorbent Assay; Female; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitemia; Real-Time Polymerase Chain Reaction | 2016 |
Hair parasite load as a new biomarker for monitoring treatment response in canine leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Biomarkers; Dog Diseases; Dogs; Hair; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasite Load | 2016 |
Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.
Topics: Animals; Antimony; Antiprotozoal Agents; Aquaglyceroporins; Dog Diseases; Dogs; Drug Resistance; Gene Expression; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Sulfhydryl Compounds | 2016 |
TLR-2 and TLR-4 transcriptions in unstimulated blood from dogs with leishmaniosis due to Leishmania infantum at the time of diagnosis and during follow-up treatment.
Topics: Allopurinol; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Follow-Up Studies; Leishmania infantum; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasite Load; Parasitemia; Toll-Like Receptor 2; Toll-Like Receptor 4; Up-Regulation | 2016 |
Evaluation of various biomarkers for kidney monitoring during canine leishmaniosis treatment.
Topics: Allopurinol; Animals; Antimetabolites; Antiprotozoal Agents; Biomarkers; Dog Diseases; Dogs; Drug Therapy, Combination; Kidney Diseases; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Proteinuria | 2017 |
Extranodal gammadelta-T-cell lymphoma in a dog with leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Leishmaniasis; Lymphoma, T-Cell; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2008 |
Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Bone Marrow; Dog Diseases; Dogs; Female; Injections, Subcutaneous; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2009 |
[Leishmaniasis: hospital and population-based incidence, and asymptomatic infection. A disease that is still with us].
Topics: Animals; Antiprotozoal Agents; Comorbidity; Disease Reservoirs; Dog Diseases; Dogs; Drug Utilization; HIV Infections; Humans; Incidence; Leishmaniasis; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Spain | 2009 |
What is your diagnosis? Peritoneal effusion from a dog.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Ascitic Fluid; Dog Diseases; Dogs; Female; Leishmania; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2009 |
Some remarks about the LeishVet directions for the treatment of canine leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Resistance; Guidelines as Topic; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2010 |
Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Follow-Up Studies; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Europe; Female; Humans; Infectious Disease Transmission, Vertical; Leishmania infantum; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phlebotomus; Treatment Outcome | 2011 |
Detection of Leishmania amastigotes in peripheral blood from four dogs--Short communication.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Fatal Outcome; Female; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2011 |
In vitro susceptibility to antimonials and amphotericin B of Leishmania infantum strains isolated from dogs in a region lacking drug selection pressure.
Topics: Algeria; Amphotericin B; Animals; Antimony Potassium Tartrate; Antiprotozoal Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Resistance; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2012 |
Tongue nodules in canine leishmaniosis--a case report.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Tongue; Tongue Diseases | 2012 |
Evaluation of the cardiac toxicity of N-methyl-glucamine antimoniate in dogs with naturally occurring leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Electrocardiography; Heart; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Prospective Studies; Troponin I | 2013 |
Distribution of liposome-encapsulated antimony in dogs.
Topics: Animals; Antiprotozoal Agents; Biological Availability; Chemistry, Pharmaceutical; Dog Diseases; Dogs; Freeze Drying; Leishmaniasis, Visceral; Liposomes; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2003 |
Use of meglumine antimoniate in canine leishmaniasis.
Topics: Adult; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Humans; Infant; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2004 |
Management of leishmanial osteolytic lesions in a hypothyroid dog by partial tarsal arthrodesis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Arthrodesis; Dog Diseases; Dogs; Hindlimb; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Tarsal Joints; Treatment Outcome | 2004 |
Granulomatous lesion on a bitch's nipple caused by Leishmania infantum.
Topics: Allopurinol; Animals; Breast Diseases; Dog Diseases; Dogs; Female; Leishmania infantum; Leishmaniasis; Meglumine; Meglumine Antimoniate; Nipples; Organometallic Compounds | 2005 |
Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibroblasts; Fluoroquinolones; Interleukin-6; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Meglumine; Meglumine Antimoniate; Mice; Nitric Oxide; Organometallic Compounds; Parasitic Sensitivity Tests; Quinolones; Tumor Necrosis Factor-alpha | 2006 |
Pancreatitis associated with N-methyl-glucamine therapy in a dog with leishmaniasis.
Topics: Acute Disease; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Leishmania; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pancreatitis | 2005 |
Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate.
Topics: Animals; Antiprotozoal Agents; Bone Marrow; Dog Diseases; Dogs; Leishmaniasis, Visceral; Liposomes; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Spectrophotometry, Atomic | 2005 |
Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate.
Topics: Animals; Antiprotozoal Agents; Carrier State; Disease Reservoirs; Dog Diseases; Dogs; Female; Injections, Subcutaneous; Leishmania; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Recurrence; Time Factors; Treatment Outcome | 2007 |
Canine leishmaniasis chemotherapy: dog's clinical condition and risk of Leishmania transmission.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Bone Marrow; Disease Transmission, Infectious; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Recurrence; Skin; Treatment Outcome; Trifluralin | 2006 |
Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Kidney; Leishmaniasis, Visceral; Liver; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2007 |
Leishmania (Viannia) braziliensis infection in two Colombian dogs: a note on infectivity for sand flies and response to treatment.
Topics: Animals; Antiprotozoal Agents; Colombia; Dog Diseases; Dogs; Leishmania braziliensis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Psychodidae | 2006 |
Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; DNA, Protozoan; Dog Diseases; Dogs; Drug Therapy, Combination; Leishmania; Leishmaniasis; Lymph Nodes; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Polymerase Chain Reaction; Skin | 2008 |
The effects of prednisone on haemostasis in leishmaniotic dogs treated with meglumine antimoniate and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Homeostasis; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Platelet Aggregation; Prednisone; Random Allocation; Risk Assessment | 2008 |
Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Follow-Up Studies; Immunotherapy; Leishmania infantum; Leishmaniasis Vaccines; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Survival Rate; T-Lymphocytes; Vaccines, Synthetic | 2008 |
A simple duplex-PCR protocol for routine diagnosis and follow up of canine leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; DNA, Kinetoplast; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmania infantum; Leishmaniasis, Visceral; Lymph Nodes; Lymphadenitis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitemia; Phosphoric Monoester Hydrolases; Polymerase Chain Reaction; Predictive Value of Tests; Sensitivity and Specificity | 2007 |
Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Insect Vectors; Leishmania infantum; Leishmaniasis, Visceral; Liposomes; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phlebotomus | 2008 |
Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
Topics: Animals; Antimony; Antiprotozoal Agents; Dog Diseases; Dogs; Leishmania; Leishmaniasis, Visceral; Liposomes; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1984 |
Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Interactions; Female; Injections, Subcutaneous; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Models, Biological; Organometallic Compounds; Paromomycin | 1995 |
Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phlebotomus; Time Factors; Treatment Outcome | 1994 |
Visceral leishmaniasis and disseminated intravascular coagulation in a dog.
Topics: Animals; Antimony; Antiprotozoal Agents; Disseminated Intravascular Coagulation; Dog Diseases; Dogs; Female; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1994 |
Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites.
Topics: Animals; Antibodies, Helminth; Antibodies, Protozoan; Antiprotozoal Agents; Dirofilaria immitis; Dirofilariasis; Dog Diseases; Dogs; Immunoglobulin G; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Toxoplasmosis, Animal | 1995 |
Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs.
Topics: Animals; Antimony; Antiprotozoal Agents; Biological Availability; Dog Diseases; Dogs; Half-Life; Injections, Intramuscular; Injections, Intravenous; Injections, Subcutaneous; Leishmania donovani; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1996 |
Osteomyelitis and arthrosynovitis associated with Leishmania donovani infection in a dog.
Topics: Animals; Antiprotozoal Agents; Diarrhea; Dog Diseases; Dogs; Fluorescent Antibody Technique, Indirect; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Osteomyelitis; Pain; Radiography; Radius; Synovial Fluid; Synovitis; Tibia; Ulna | 1997 |
Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Carriers; Injections, Intramuscular; Injections, Subcutaneous; Leishmaniasis; Liposomes; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1997 |
Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs.
Topics: Animals; Antibodies, Protozoan; Antibody Formation; Antiprotozoal Agents; B-Lymphocytes; Dog Diseases; Dogs; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Immunity, Cellular; Immunoglobulin G; Leishmania infantum; Leishmaniasis, Visceral; Lymphocyte Subsets; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; T-Lymphocytes | 1997 |
Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
Topics: Analysis of Variance; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Administration Schedule; Injections, Subcutaneous; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Metabolic Clearance Rate; Organometallic Compounds | 1998 |
Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin; Treatment Outcome | 1998 |
Effects of antimonial therapy for canine leishmaniasis on antibody titer.
Topics: Allopurinol; Animals; Antibodies, Protozoan; Antimony; Antiprotozoal Agents; Dog Diseases; Dogs; Fluorescent Antibody Technique, Indirect; Follow-Up Studies; Injections, Intramuscular; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Regression Analysis; Time Factors | 1998 |
Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis.
Topics: Allopurinol; Animals; Antimony; Antiprotozoal Agents; Dog Diseases; Dogs; Follow-Up Studies; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Regression Analysis; Serum Albumin; Serum Globulins; Time Factors | 1998 |
Value of Western blotting in the clinical follow-up of canine leishmaniasis.
Topics: Allopurinol; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Blotting, Western; Disease Progression; Dog Diseases; Dogs; Enzyme Inhibitors; Fluorescent Antibody Technique, Indirect; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Sensitivity and Specificity; Treatment Outcome | 1999 |
Disposition of antimony and aminosidine combination after multiple subcutaneous injections in dogs.
Topics: Amebicides; Animals; Antimony; Antiprotozoal Agents; Area Under Curve; Chromatography, Liquid; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Fluorometry; Half-Life; Injections, Subcutaneous; Least-Squares Analysis; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin; Spectrophotometry, Atomic | 1999 |
Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Biopsy; Blood; Blotting, Western; Dog Diseases; Dogs; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Leishmania infantum; Leishmaniasis, Visceral; Lymph Nodes; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Skin | 1999 |
PCR follow-up examination after treatment of canine leishmaniosis (CaL).
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Follow-Up Studies; Humans; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Polymerase Chain Reaction; Sensitivity and Specificity; Species Specificity | 1998 |
Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.
Topics: Allopurinol; Animals; Antibodies, Protozoan; Antibody Specificity; Antiprotozoal Agents; Dog Diseases; Dogs; Endemic Diseases; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Immunoglobulin G; Leishmania infantum; Leishmaniasis, Visceral; Longitudinal Studies; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Seroepidemiologic Studies; Spain | 2001 |
In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
Topics: Animals; Antimony; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Resistance; Humans; Leishmania infantum; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests | 2002 |
Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Cell Division; Diptera; Dog Diseases; Dogs; Female; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Immunotherapy; Leishmania infantum; Leishmaniasis, Visceral; Lymphocyte Subsets; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2002 |
Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
Topics: Animals; Antiprotozoal Agents; Disease Reservoirs; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Resistance; Female; Leishmania donovani; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds | 1992 |
[Parasitological and immunological progress control during and after chemotherapy of canine leishmaniasis].
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Leishmania donovani; Leishmaniasis, Visceral; Lymph Nodes; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1992 |
Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Insect Vectors; Leishmania donovani; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phlebotomus | 1987 |
Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Fluorescent Antibody Technique; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1988 |
Glomerulonephritis in dogs with canine leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Complement C3; Dog Diseases; Dogs; Glomerulonephritis; Immunoglobulin G; Kidney; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1988 |
Studies on canine leishmaniasis control. 2. Effectiveness of control measures against canine leishmaniasis in the Isle of Elba, Italy.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Italy; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1988 |
[Visceral leishmaniasis in Santarem/PA: general aspects of the control, serological survey in dogs and treatment of the human cases].
Topics: Adolescent; Adult; Animals; Brazil; Child; Child, Preschool; Dog Diseases; Dogs; Humans; Infant; Insect Control; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Psychodidae | 1985 |